C反应蛋白检测市场－全球产业规模、份额、趋势、机会及预测（依检测类型、检测范围、疾病领域、最终用途产业、地区及竞争格局划分，2021-2031年）

全球 C 反应蛋白检测市场预计将从 2025 年的 19.5 亿美元成长到 2031 年的 22.1 亿美元，复合年增长率为 2.11%。

这种诊断方法可定量检测血液样本中的C反应蛋白，C反应蛋白是全身性发炎、细菌感染疾病和心血管风险的重要生物标记。推动市场成长的主要因素是慢性心血管疾病和发炎性疾病发生率的上升，这些疾病需要病患监测和风险评估。例如，美国心臟协会（AHA）报告称，到2025年，全球心血管疾病患病人数将达到约6.12亿，凸显了发炎标记的重要性。此外，全球人口老化以及向分散式就地检验解决方案的显着转变也是推动市场成长的因素。

然而，阻碍市场发展的主要障碍是严格的监管环境和各地不同的报销政策。这些行政和经济障碍往往会延缓新型检测平台的商业性审批，并限制医疗机构使用高灵敏度诊断工具的经济可行性。因此，这些障碍阻碍了先进诊断解决方案的广泛应用和市场渗透。

市场驱动因素

慢性病和发炎性疾病负担的日益加重，是推动全球C反应蛋白检测市场发展的主要动力。全身性发炎是心血管疾病、糖尿病和自体免疫疾病的核心组成部分，因此，临床上对精准生物标记追踪疾病进展的需求日益增长。鑑于非传染性疾病的广泛影响，医疗专业人员越来越多地利用C反应蛋白检测进行发炎的早期发现和有效治疗。根据世界卫生组织（世卫组织）2024年4月发布的概况介绍，非传染性疾病每年导致4,100万人死亡，占全球死亡总数的74%。这项数据凸显了製定严格诊断通讯协定的必要性，以及医院和门诊对C反应蛋白检测的迫切需求。

同时，就地检验平台的日益普及也正在影响市场格局。这些平台分散了诊断流程，并能加快临床决策速度。这些携带式设备无需前往传统检查室即可进行即时蛋白质水平分析，有助于区分细菌感染和病毒感染，并最大限度地减少不恰当的抗生素使用。主要製造商正在扩展其产能，以适应医疗服务分散化的趋势。例如，雅培公司在2024年10月发布的财务报告中显示，全球整体诊断业务销售额达24亿美元，凸显了市场对便利诊断工具的持续需求。此外，联合国发布的2024年人口趋势报告显示，全球65岁及以上人口将显着增长，将增加易患发炎性疾病的患者群体，并提高对定期健康监测的需求。

市场挑战

全球C反应蛋白检测市场的成长受到严格法规环境和不一致的报销策略的显着限制。製造商必须应对复杂且不断变化的合规标准，这延长了核准流程并增加了研发成本。这种监管压力迫使企业将大量资金从高灵敏度检测的研发中转移，减缓了新型先进诊断技术的推出。因此，核准流程的不确定性阻碍了新产品在关键市场的上市，并限制了医疗服务提供者可用于有效病患监测的诊断选择。

除了监管障碍外，不明确的报销机制也带来了财务风险，阻碍了这些检测技术的广泛应用。临床检查室往往在没有明确支付保障的情况下，不愿意投资现代诊断平台，这直接阻碍了市场渗透。 MedTech Europe发布的2025年数​​据显示，体外诊断医疗设备法规（IVDR）下的认证成本较先前的标准飙升了高达100%。这导致选择欧盟作为主要上市区域的主要製造商数量下降了40%。这表明，行政和经济壁垒正在切实限制市场扩张的潜力。

市场趋势

随着医疗系统将诊断演算法纳入国家抗击抗菌药物抗药性策略，C反应蛋白（CRP）检测在抗菌药物管理计画中的应用正从根本上改变市场需求。为了确保与全球抗菌药物管理目标保持一致，越来越多的医疗机构通讯协定要求在应用抗生素前进行CRP筛检，这使得该检测从标准诊断工具提升为监管合规的关键组成部分。这种转变推动了快速检测平台的采购，使其成为检验公共卫生合规性的关键基础设施，尤其是在呼吸道感染疾病治疗方法选择方面。正如雅培公司2024年1月发表的一篇报导所述，就地检验结合沟通训练已被证明可将抗生素处方量减少60%以上。

同时，高敏C反应蛋白（hs-CRP）在心血管风险分层中的广泛应用，正将这项检测的范围从急性发炎监测扩展到长期预防性心臟病学。临床医师越来越重视hs-CRP在检测无症状个体残余发炎风险的应用，从而能够采取早期疗育策略，补充传统的血脂管理。随着越来越多的临床证据支持生物标记能够预测未来不利事件，这一趋势正在加速发展，促使医疗保健机构将这些检测纳入常规筛检。例如，2024年8月在欧洲心臟病学会（ESC）大会上发表的一项研究表明，与C反应蛋白水平最低的女性相比，C反应蛋白水平高的女性患心臟病的风险增加了70%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球C反应蛋白检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依检测类型（免疫比浊法、酵素连结免疫吸附试验、化学冷光免疫检测、其他）
  • 依检测范围（高灵敏度CRP、常规CRP、cCRP）
  • 依疾病领域（心血管疾病、癌症、类风湿性关节炎、发炎性肠道疾病、子宫内膜异位症、全身性红斑性狼疮、其他）
  • 按最终用户行业（医院/诊所、检查室、疗养院、居家医疗、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美C反应蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲C反应蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区C反应蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲C反应蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲C反应蛋白检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球C反应蛋白检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global C-reactive Protein Testing Market is projected to expand from USD 1.95 Billion in 2025 to USD 2.21 Billion by 2031, reflecting a CAGR of 2.11%. This diagnostic method, which quantifies C-reactive protein in blood samples, serves as a vital biomarker for systemic inflammation, bacterial infections, and cardiovascular risks. Growth is largely fueled by the rising incidence of chronic cardiovascular and inflammatory conditions that require ongoing patient monitoring and risk assessment. For instance, the American Heart Association reported that the global prevalence of cardiovascular disease reached approximately 612 million cases in 2025, highlighting the critical need for inflammatory markers. Additionally, the market is bolstered by an aging global population and a noticeable transition toward decentralized point-of-care testing solutions.

However, a major obstacle hindering market progress is the strict regulatory landscape combined with variable reimbursement policies across different regions. These administrative and economic hurdles often postpone the commercial authorization of novel testing platforms and restrict the financial viability of high-sensitivity diagnostic tools for healthcare providers. Consequently, these barriers limit the broader adoption and market penetration of advanced diagnostic solutions.

Market Driver

The escalating burden of chronic and inflammatory diseases acts as a primary engine for the Global C-reactive Protein Testing Market's development. Because systemic inflammation is a core component of cardiovascular diseases, diabetes, and autoimmune conditions, the clinical imperative for precise biomarkers to track disease progression has grown stronger. Medical professionals are increasingly utilizing C-reactive protein assays for early inflammation detection and effective therapy management, especially considering the vast impact of noncommunicable diseases. According to the World Health Organization's April 2024 fact sheet, noncommunicable diseases are responsible for 41 million deaths annually, accounting for 74% of global mortality, a statistic that underscores the necessity for rigorous diagnostic protocols and high demand for testing in both hospital and outpatient environments.

Simultaneously, the market is being shaped by the growing integration of point-of-care testing platforms, which decentralize diagnostic processes and facilitate swift clinical decision-making. These portable devices enable immediate protein level analysis outside of traditional laboratories, aiding in the differentiation between bacterial and viral infections and helping to minimize inappropriate antibiotic use. Major manufacturers are expanding their capabilities to address this shift towards decentralized care; for example, Abbott reported worldwide Diagnostics sales of USD 2.4 billion in their October 2024 results, highlighting the persistent demand for accessible diagnostic tools. Furthermore, demographic trends identified by the United Nations in 2024 indicate a significant rise in the global population aged 65 and older, increasing the patient base susceptible to inflammatory conditions and driving the need for regular health monitoring.

Market Challenge

Growth in the Global C-reactive Protein Testing Market is heavily constrained by a rigorous regulatory environment and inconsistent reimbursement strategies. Manufacturers must navigate complex and shifting compliance standards that prolong approval processes and escalate development expenses. This regulatory pressure forces companies to divert crucial capital away from the research and development of high-sensitivity assays, thereby delaying the commercial launch of advanced diagnostic innovations. As a result, the uncertainty surrounding approval pathways often deters companies from introducing new products in major markets, ultimately limiting the diagnostic options available to healthcare providers for effective patient monitoring.

In addition to regulatory hurdles, ambiguous reimbursement frameworks introduce financial risks that inhibit the uptake of these tests. Clinical laboratories are frequently hesitant to invest in modern diagnostic platforms lacking clear payment assurances, a factor that directly impedes market penetration. Data from MedTech Europe in 2025 highlighted the severity of this issue, revealing that certification costs under the In Vitro Diagnostic Regulation surged by up to 100% compared to earlier standards, prompting a 40% reduction in large manufacturers choosing the European Union as their primary launch region. This demonstrates how administrative and economic impediments actively suppress the market's potential for broader expansion.

Market Trends

The utilization of CRP testing within Antimicrobial Stewardship Programs is fundamentally transforming market demand as healthcare systems incorporate diagnostic algorithms into national strategies against drug resistance. Institutional protocols increasingly require CRP screening before antibiotic administration to ensure alignment with global stewardship objectives, thereby elevating the assay from a standard diagnostic tool to a vital element of regulatory compliance. This shift drives the acquisition of rapid testing platforms as critical infrastructure for public health adherence, particularly for validating treatment choices in respiratory infections. As noted in an Abbott article from January 2024, utilizing C-reactive protein point-of-care testing alongside communication training has been demonstrated to decrease antibiotic prescribing by over 60%.

Concurrently, the widespread application of High-Sensitivity CRP (hs-CRP) for cardiovascular risk stratification is broadening the test's scope from monitoring acute inflammation to long-term preventative cardiology. Clinicians are placing greater emphasis on hs-CRP to detect residual inflammatory risks in asymptomatic individuals, enabling early intervention strategies that complement traditional lipid management. This trend is gaining momentum as fresh clinical evidence confirms the biomarker's ability to predict future adverse events over long periods, encouraging providers to add these assays to routine screenings. For instance, research presented at the European Society of Cardiology Congress in August 2024 indicated that women with elevated C-reactive protein levels faced a 70% higher risk of heart disease compared to those with the lowest levels.

Key Market Players

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

Report Scope

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

C-reactive Protein Testing Market, By Assay Type

• Immunoturbidimetric Assay
• ELISA
• Chemiluminescence Immunoassay
• Others

C-reactive Protein Testing Market, By Detection Range

• hs-CRP
• Conventional CRP
• cCRP

C-reactive Protein Testing Market, By Disease Area

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others

C-reactive Protein Testing Market, By End-Use Industry

• Hospitals & Clinics
• Laboratories
• Assisted Living Healthcare Facilities
• Homecare
• Others

C-reactive Protein Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

Global C-reactive Protein Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global C-reactive Protein Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others)
  • 5.2.2. By Detection Range (hs-CRP, Conventional CRP, cCRP)
  • 5.2.3. By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others)
  • 5.2.4. By End-Use Industry (Hospitals & Clinics, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America C-reactive Protein Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Assay Type
  • 6.2.2. By Detection Range
  • 6.2.3. By Disease Area
  • 6.2.4. By End-Use Industry
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States C-reactive Protein Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Assay Type
      • 6.3.1.2.2. By Detection Range
      • 6.3.1.2.3. By Disease Area
      • 6.3.1.2.4. By End-Use Industry
  • 6.3.2. Canada C-reactive Protein Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Assay Type
      • 6.3.2.2.2. By Detection Range
      • 6.3.2.2.3. By Disease Area
      • 6.3.2.2.4. By End-Use Industry
  • 6.3.3. Mexico C-reactive Protein Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Assay Type
      • 6.3.3.2.2. By Detection Range
      • 6.3.3.2.3. By Disease Area
      • 6.3.3.2.4. By End-Use Industry

7. Europe C-reactive Protein Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Assay Type
  • 7.2.2. By Detection Range
  • 7.2.3. By Disease Area
  • 7.2.4. By End-Use Industry
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany C-reactive Protein Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Assay Type
      • 7.3.1.2.2. By Detection Range
      • 7.3.1.2.3. By Disease Area
      • 7.3.1.2.4. By End-Use Industry
  • 7.3.2. France C-reactive Protein Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Assay Type
      • 7.3.2.2.2. By Detection Range
      • 7.3.2.2.3. By Disease Area
      • 7.3.2.2.4. By End-Use Industry
  • 7.3.3. United Kingdom C-reactive Protein Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Assay Type
      • 7.3.3.2.2. By Detection Range
      • 7.3.3.2.3. By Disease Area
      • 7.3.3.2.4. By End-Use Industry
  • 7.3.4. Italy C-reactive Protein Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Assay Type
      • 7.3.4.2.2. By Detection Range
      • 7.3.4.2.3. By Disease Area
      • 7.3.4.2.4. By End-Use Industry
  • 7.3.5. Spain C-reactive Protein Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Assay Type
      • 7.3.5.2.2. By Detection Range
      • 7.3.5.2.3. By Disease Area
      • 7.3.5.2.4. By End-Use Industry

8. Asia Pacific C-reactive Protein Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Assay Type
  • 8.2.2. By Detection Range
  • 8.2.3. By Disease Area
  • 8.2.4. By End-Use Industry
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China C-reactive Protein Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Assay Type
      • 8.3.1.2.2. By Detection Range
      • 8.3.1.2.3. By Disease Area
      • 8.3.1.2.4. By End-Use Industry
  • 8.3.2. India C-reactive Protein Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Assay Type
      • 8.3.2.2.2. By Detection Range
      • 8.3.2.2.3. By Disease Area
      • 8.3.2.2.4. By End-Use Industry
  • 8.3.3. Japan C-reactive Protein Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Assay Type
      • 8.3.3.2.2. By Detection Range
      • 8.3.3.2.3. By Disease Area
      • 8.3.3.2.4. By End-Use Industry
  • 8.3.4. South Korea C-reactive Protein Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Assay Type
      • 8.3.4.2.2. By Detection Range
      • 8.3.4.2.3. By Disease Area
      • 8.3.4.2.4. By End-Use Industry
  • 8.3.5. Australia C-reactive Protein Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Assay Type
      • 8.3.5.2.2. By Detection Range
      • 8.3.5.2.3. By Disease Area
      • 8.3.5.2.4. By End-Use Industry

9. Middle East & Africa C-reactive Protein Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Assay Type
  • 9.2.2. By Detection Range
  • 9.2.3. By Disease Area
  • 9.2.4. By End-Use Industry
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia C-reactive Protein Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Assay Type
      • 9.3.1.2.2. By Detection Range
      • 9.3.1.2.3. By Disease Area
      • 9.3.1.2.4. By End-Use Industry
  • 9.3.2. UAE C-reactive Protein Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Assay Type
      • 9.3.2.2.2. By Detection Range
      • 9.3.2.2.3. By Disease Area
      • 9.3.2.2.4. By End-Use Industry
  • 9.3.3. South Africa C-reactive Protein Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Assay Type
      • 9.3.3.2.2. By Detection Range
      • 9.3.3.2.3. By Disease Area
      • 9.3.3.2.4. By End-Use Industry

10. South America C-reactive Protein Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Assay Type
  • 10.2.2. By Detection Range
  • 10.2.3. By Disease Area
  • 10.2.4. By End-Use Industry
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil C-reactive Protein Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Assay Type
      • 10.3.1.2.2. By Detection Range
      • 10.3.1.2.3. By Disease Area
      • 10.3.1.2.4. By End-Use Industry
  • 10.3.2. Colombia C-reactive Protein Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Assay Type
      • 10.3.2.2.2. By Detection Range
      • 10.3.2.2.3. By Disease Area
      • 10.3.2.2.4. By End-Use Industry
  • 10.3.3. Argentina C-reactive Protein Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Assay Type
      • 10.3.3.2.2. By Detection Range
      • 10.3.3.2.3. By Disease Area
      • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global C-reactive Protein Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Danaher Corp
• 15.4. Quest Diagnostics
• 15.5. Siemens Healthineers AG
• 15.6. Abbott Laboratories Inc.
• 15.7. Merck KGaAA
• 15.8. Zoetis Inc.
• 15.9. Ortho Clinical Diagnostics
• 15.10. Getein Biotech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer